165 related articles for article (PubMed ID: 31975354)
41. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Gibson CM; Chi G; Halaby R; Korjian S; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Gold A; Bandman O; Harrington RA; Cohen AT;
Circulation; 2017 Feb; 135(7):648-655. PubMed ID: 27881569
[TBL] [Abstract][Full Text] [Related]
42. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
[TBL] [Abstract][Full Text] [Related]
43. Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
Bauersachs R; Lee AYY; Kamphuisen PW; Meyer G; Janas MS; Jarner MF; Khorana AA;
Thromb Haemost; 2018 May; 118(5):914-921. PubMed ID: 29618162
[TBL] [Abstract][Full Text] [Related]
44. Low-molecular-weight heparin and mortality in acutely ill medical patients.
Kakkar AK; Cimminiello C; Goldhaber SZ; Parakh R; Wang C; Bergmann JF;
N Engl J Med; 2011 Dec; 365(26):2463-72. PubMed ID: 22204723
[TBL] [Abstract][Full Text] [Related]
45. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
[TBL] [Abstract][Full Text] [Related]
46. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Loke YK; Kwok CS
J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
[TBL] [Abstract][Full Text] [Related]
47. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
Ning GZ; Kan SL; Chen LX; Shangguan L; Feng SQ; Zhou Y
Sci Rep; 2016 Mar; 6():23726. PubMed ID: 27020475
[TBL] [Abstract][Full Text] [Related]
48. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Nicklaus MD; Ludwig SL; Kettle JK
J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
[TBL] [Abstract][Full Text] [Related]
49. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
[TBL] [Abstract][Full Text] [Related]
50. The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population.
Kingdon LK; Miller EM; Savage SA
J Surg Res; 2019 Dec; 244():509-515. PubMed ID: 31336243
[TBL] [Abstract][Full Text] [Related]
51. Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Venker BT; Ganti BR; Lin H; Lee ED; Nunley RM; Gage BF
J Arthroplasty; 2017 Feb; 32(2):645-652. PubMed ID: 27823844
[TBL] [Abstract][Full Text] [Related]
52. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
Prandoni P; Prins MH; Cohen AT; Müller K; Pap ÁF; Tewes MC; Lensing AW
Acad Emerg Med; 2015 Feb; 22(2):142-9. PubMed ID: 25676529
[TBL] [Abstract][Full Text] [Related]
53. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
Snoga JL; Benitez RM; Kim S; Creager O; Lusk KA
Am J Health Syst Pharm; 2021 Jun; 78(12):1057-1065. PubMed ID: 33580664
[TBL] [Abstract][Full Text] [Related]
54. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Patel AA; Ogden K; Mody SH; Bookhart B
J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
[TBL] [Abstract][Full Text] [Related]
55. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
[TBL] [Abstract][Full Text] [Related]
56. Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients.
Lee JJ; Memar Montazerin S; Shojaei F; Chi G
Ther Clin Risk Manag; 2021; 17():471-487. PubMed ID: 34079269
[TBL] [Abstract][Full Text] [Related]
57. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Anderson DR; Dunbar M; Murnaghan J; Kahn SR; Gross P; Forsythe M; Pelet S; Fisher W; Belzile E; Dolan S; Crowther M; Bohm E; MacDonald SJ; Gofton W; Kim P; Zukor D; Pleasance S; Andreou P; Doucette S; Theriault C; Abianui A; Carrier M; Kovacs MJ; Rodger MA; Coyle D; Wells PS; Vendittoli PA
N Engl J Med; 2018 Feb; 378(8):699-707. PubMed ID: 29466159
[TBL] [Abstract][Full Text] [Related]
58. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
59. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
Wang Y; Wang M; Ni Y; Liang Z
Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
[No Abstract] [Full Text] [Related]
60. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
